Comparative Pharmacology
Head-to-head clinical analysis: LAMPRENE versus RIFABUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPRENE versus RIFABUTIN.
LAMPRENE vs RIFABUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofazimine binds preferentially to mycobacterial DNA, inhibiting replication and exerting antimicrobial activity. It also has anti-inflammatory properties by modulating immune responses.
Inhibits DNA-dependent RNA polymerase in susceptible bacteria, blocking RNA synthesis.
300 mg orally once daily in combination with other antimycobacterial agents.
300 mg orally once daily. For Mycobacterium avium complex (MAC) prophylaxis, 300 mg once daily. For active tuberculosis (in combination therapy), 5 mg/kg (up to 300 mg) orally once daily or 5 times weekly.
None Documented
None Documented
Terminal elimination half-life ranges from 8 to 70 days (mean approximately 14 days) due to extensive tissue storage and slow release; may be longer with chronic dosing.
Clinical Note
moderateRifabutin + Digoxin
"The metabolism of Digoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Rifabutin."
Clinical Note
moderateRifabutin + Clobetasol propionate
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Rifabutin."
Clinical Note
moderateRifabutin + Estrone sulfate
45 hours (range 32-67 hours) in adults; terminal elimination half-life decreases to 17 hours after repeated dosing due to autoinduction of metabolism.
Primarily fecal (unabsorbed drug and biliary excretion); renal excretion accounts for <1% of the dose as unchanged drug and metabolites.
Renal (53% as unchanged drug and metabolites), fecal (30%), with biliary excretion contributing to enterohepatic recycling.
Category C
Category A/B
Antimycobacterial
Antimycobacterial
"The metabolism of Estrone sulfate can be increased when combined with Rifabutin."